Evidence map›Paper›PMID 37902861›Full record

ArticleEJNMMI research2023

Effects of novel androgen receptor signaling inhibitors on PSMA PET signal intensity in patients with castrate-resistant prostate cancer: a prospective exploratory serial imaging study.

Ida Sonni, Andrei Gafita, Lena M Unterrainer, Rejah M Alano, Stephanie Lira, John Shen, Alexandra Drakaki, Tristan Grogan, Matthew B Rettig, Johannes Czernin and 1 more

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04279561 (Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer), which is not on this map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04279561 phase1terminatednot on this map

Effects of Novel Androgen Receptor Signaling Inhibitors on PSMA PET Signal Intensity in Patients With Castrate-Resistant Prostate Cancer: A Prospective Exploratory Study

TypeinterventionalSponsorJonsson Comprehensive Cancer CenterRan2020 to 2022Enrolled9ConditionsCastration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8ArmsComputed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Effects of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing [European journal of nuclear medicine and molecular imaging · 2026
    Article
  4. PSMA expression assessed by [Cancer imaging : the official publication of the International Cancer Imaging Society · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Correlation of [European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 3 countries.

Ida SonniDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA. isonni@mednet.ucla.edu.ORCID http://orcid.org/0000-0002-8802-7704
Andrei GafitaDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Lena M UnterrainerDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Rejah M AlanoDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Stephanie LiraDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
John ShenDepartment of Medical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Alexandra DrakakiDepartment of Medical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Tristan GroganDepartment of Medicine Statistics Core, University of California, Los Angeles, Los Angeles, CA, USA.
Matthew B RettigDepartment of Medical Oncology, University of California, Los Angeles, Los Angeles, CA, USA.
Johannes CzerninDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
Jeremie CalaisDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA, USA.
University of California, Los Angeles · US

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
NCI NIH HHS P50 CA211015
6 · The paper itself

Abstract

backgroundPSMA expression is influenced by hormonal status. We evaluated changes in PSA and whole-body 68Ga-PSMA-11 PET/CT (WB-PSMA PET) after initiation of androgen receptor signaling inhibitors (ARSi).

methodsProspectively enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) initiating ARSi underwent serial PSA measurements and WB-PSMA PET at baseline, 1-week, and 3-months post-ARSi. We correlated WB-PSMA PET metrics and PSA kinetics after ARSi to 1-year clinical outcome.

resultsDue to low enrollment rate, the study was closed before reaching the recruitment goal of 30 patients. Nine patients were enrolled. At 1-year, unfavorable outcome was documented in 6/9 (66%) patients. Nine/9 patients completed PSMA PET at 1-week, 5/9 at 3-months. Changes in PSA, PSMA-VOL, SUVmean and SUVmax were - 12%, + 5%, + 3%, and + 10% at 1-week, - 42%, - 16%, - 15% and - 17% at 3-months, respectively.

conclusionsOur prospective trial involving 9 mCRPC patients initiating ARSi did not show significant modulation of PSMA expression measured on WB-PSMA PET at 1-week. This study was registered on clinicaltrials.gov (NCT04279561).

Indexed as

Androgen receptorHormonal treatmentProstate cancerPSMA flarePSMA PET

Identifiers

PMID37902861
PMCPMC10616012
OpenAlexW4388021292

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.